DAWN insider trading
HealthcareDay One Biopharmaceuticals, Inc.: insider trade history from SEC Form 4 filings.
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Company website: dayonebio.com
DAWN insider activity at a glance
FilingIQ tracks 418 insider transactions for DAWN in filings since Jun 1, 2021. The most recent transaction is dated Apr 23, 2026.
Across the full history, 17 open-market purchases
and 181 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on DAWN insider trades is 51.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest DAWN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for DAWN?
- FilingIQ tracks 418 Form 4 insider transactions for DAWN (Day One Biopharmaceuticals, Inc.), covering filings from Jun 1, 2021 onwards. 0 of those are dated within the last 90 days.
- Are DAWN insiders net buyers or net sellers?
- Across the full Form 4 history for DAWN, 17 transactions (4%) were open-market purchases and 181 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DAWN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is DAWN in?
- Day One Biopharmaceuticals, Inc. (DAWN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.19B.
Methodology & sources
Every DAWN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.